Sermorelin

Sermorelin, also known as GRF 1-29, Geref, or sermorelin acetate, is a synthetic Growth Hormone peptide that serves as a GHRH analogue in laboratory research. This research compound mimics the action of growth hormone-releasing hormone (GHRH) and has been extensively studied for its effects on endogenous growth hormone regulation. In research models, sermorelin demonstrates its mechanism of action by binding to GHRH receptors on pituitary cells, thereby stimulating the release of endogenous growth hormone. This process enhances the natural pulsatile secretion of growth hormone, which plays a crucial role in growth and metabolic processes. Studies indicate that this synthetic peptide maintains the physiological rhythm of growth hormone release rather than providing exogenous hormone directly. Research has documented several primary effects of sermorelin in laboratory studies. Investigations show increases in endogenous growth hormone levels, with subsequent improvements in body composition through reduced fat mass. Studies indicate enhanced muscle-regulatory pathways and strength parameters, alongside support for bone density measurements. Additionally, research models have demonstrated improvements in sleep quality metrics. The evidence grade for sermorelin research is classified as B, indicating moderate research support. Several human trials have demonstrated the compound's ability to increase growth hormone levels and improve body composition parameters in research settings. However, most available studies are characterised as small-scale and short-term investigations, with limited data available regarding long-term safety profiles and sustained efficacy in extended study designs. This synthetic GHRH analogue continues to be of significant interest in growth hormone research, particularly for studies examining natural growth hormone regulation and its associated physiological effects.